0001193125-15-210649.txt : 20150702 0001193125-15-210649.hdr.sgml : 20150702 20150602163059 ACCESSION NUMBER: 0001193125-15-210649 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20150602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OCULAR THERAPEUTIX, INC CENTRAL INDEX KEY: 0001393434 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 34 CROSBY DRIVE STREET 2: SUITE 105 CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-895-3235 MAIL ADDRESS: STREET 1: 34 CROSBY DRIVE STREET 2: SUITE 105 CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: I-THERAPEUTIX INC DATE OF NAME CHANGE: 20070315 CORRESP 1 filename1.htm CORRESP

OCULAR THERAPEUTIX, INC.

34 CROSBY DRIVE, SUITE 105

BEDFORD, MA 01730

June 2, 2015

Via EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re: Ocular Therapeutix, Inc.
Registration Statement on Form S-1
File No. 333-204344
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Ocular Therapeutix, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-204344), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on June 4, 2015, or as soon thereafter as practicable.

The Registrant hereby acknowledges that:

 

(a) should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;

 

(b) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

 

(c) the Registrant may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

[The remainder of this page is intentionally left blank.]

Very truly yours,
Ocular Therapeutix, Inc.
By: /s/ W. Bradford Smith
Name: W. Bradford Smith
Title: Chief Financial Officer

[Signature Page to Request for Acceleration]